AHPA Stock Price, News & Analysis

AHPA NASDAQ

Company Description

Welcome to the overview page for AHPA (AHPA), where you can find comprehensive stock information and company updates.

Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.

Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

- %

Performance 1 year

$176.1M

Market Cap

23.0M

Shares outstanding

Latest News

View All

October 26, 2022

0.00%

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

October 24, 2022

0.00%

OmniAb Business Combination Approved by APAC Shareholders

October 3, 2022

0.00%

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

October 3, 2022

0.44%

Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination

acquisition

August 24, 2022

0.00%

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

May 4, 2022

0.00%

Ligand Reports First Quarter 2022 Financial Results

earnings

SEC Filings

View All

No SEC filings available for AHPA.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of AHPA (AHPA)?

The market cap of AHPA (AHPA) is approximately 176.1M.